Red Rock Regeneration Inc.
The goal of this retrospective chart review study is to assess safety of NMP® in the treatment of cervical spine degenerative conditions by assessing the incidence and nature of AEs in follow-up (minimum of 90 days and up to 2 year post-operatively) as well as reoperation rates.
Interbody fusion is a cornerstone of spinal reconstruction, involving placement of a bone graft within the intervertebral space to achieve fusion between adjacent vertebrae. Autogenous bone graft (ABG), typically harvested from the iliac crest, is considered the gold standard due to its osteogenic potential. However, ABG use is limited by donor site morbidity, infection risk, increased operative time, blood loss, and limited graft availability. Alternative graft materials, such as recombinant human bone morphogenetic protein-2 (rhBMP-2) and demineralized bone matrix (DBM), have been developed…
Inclusion Criteria: 1. Patients treated with NMP® for Cervical (C2-T1) Interbody fusion (2022-2025) at the study site. 2. Minimum of 90-day post-operative follow up data available Exclusion Criteria: * Patients with no follow-up data within 3 months from the surgery date due to missed postoperative appointments.
Human bone allograft
Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
Arctuva estimate
Verify or correct the compensation shown for this listing.